Amna Ibrahim
Overview
Explore the profile of Amna Ibrahim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elanwar R, Al Masry H, Ibrahim A, Hussein M, Ibrahim S, Masoud M
BMC Neurol
. 2023 Sep;
23(1):330.
PMID: 37723424
Background: Visual dysfunction have been well reported as one of the non-motor symptoms in Parkinson's disease (PD). The aim of this study was to evaluate the functional and structural changes...
2.
Lee D, Gittleman H, Weinstock C, Suzman D, Bloomquist E, Agrawal S, et al.
Eur Urol
. 2023 Jun;
84(4):373-378.
PMID: 37271635
Background: While frontline immuno-oncology/tyrosine kinase inhibitor (IO/TKI) combination therapy has established a benefit in metastatic renal cell carcinoma (mRCC), this may differ by International Metastatic RCC Database Consortium (IMDC) risk...
3.
Fallah J, Agrawal S, Gittleman H, Fiero M, Subramaniam S, John C, et al.
Clin Cancer Res
. 2022 Dec;
29(9):1651-1657.
PMID: 36469000
On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant...
4.
Fallah J, Brave M, Weinstock C, Mehta G, Bradford D, Gittleman H, et al.
Clin Cancer Res
. 2022 Jun;
28(22):4843-4848.
PMID: 35727604
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal...
5.
Arora S, Narayan P, Osgood C, Wedam S, Prowell T, Gao J, et al.
Clin Cancer Res
. 2021 Oct;
28(6):1072-1086.
PMID: 34711632
Over the last decade, the treatment of patients with breast cancer has been greatly impacted by the approval of multiple drugs and indications. This summary describes 30 FDA approvals of...
6.
Arora S, Narayan P, Ison G, Berman T, Suzman D, Wedam S, et al.
Clin Cancer Res
. 2021 Oct;
28(6):1058-1071.
PMID: 34711631
Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food...
7.
Chang E, Weinstock C, Zhang L, Fiero M, Zhao M, Zahalka E, et al.
Clin Cancer Res
. 2021 Aug;
28(3):441-445.
PMID: 34417198
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior...
8.
Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V, et al.
Lancet Oncol
. 2021 Jul;
22(9):1230-1239.
PMID: 34310904
Background: Little is known about the benefit-risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of...
9.
Amatya A, Fiero M, Bloomquist E, Sinha A, Lemery S, Singh H, et al.
Clin Cancer Res
. 2021 Jun;
27(21):5753-5756.
PMID: 34117032
Subgroup analyses are assessments of treatment effects based on certain patient characteristics out of the total study population and are important for interpretation of pivotal oncology trials. However, appropriate use...
10.
Anscher M, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, et al.
Oncologist
. 2020 Nov;
26(2):139-146.
PMID: 33145877
The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate-resistant...